Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620187 · ClinicalTrials.gov registry record · Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
A Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 12
- Study locations
NCT04620187 is a Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants, roughly in line with the 59-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target. The trial reports 12 study locations across 5 states.
The verdict
NCT04620187, a Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Conditions Studied
Interventions
- DRUG Standard of Care Chemotherapy
- DRUG Ado-trastuzumab (T) emtansine (T-DM1)
- RADIATION Standard of Care Radiotherapy
Study Locations (12)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- University of Chicago - Chicago
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-12-24 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620187
The ClinicalTrials.gov registry entry for NCT04620187 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 59-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Salivary Gland Cancer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Chemotherapy is the first listed.
NCT04620187 reports 12 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04620187 about?
NCT04620187 is a clinical study titled "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas". This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuz...
What is the current status of trial NCT04620187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-12-24. Estimated completion is 2029-02-01.
What conditions does trial NCT04620187 study?
This clinical trial studies the following conditions: Salivary Gland Cancer, HER2 Gene Mutation.
What interventions are being tested in trial NCT04620187?
The interventions under investigation include: Standard of Care Chemotherapy (DRUG), Ado-trastuzumab (T) emtansine (T-DM1) (DRUG), Standard of Care Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT04620187?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04620187 being conducted?
This trial has 12 study locations across Illinois, Massachusetts, New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Amivantamab in Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.